AACR Elects ImaginAb Science Advisory Board Member, Dr. Antoni Ribas, as President-Elect at 2019 Annual Meeting

LOS ANGELES, 4 April 2019 – ImaginAb Inc., a clinical stage immuno-oncology imaging company, congratulates Dr. Antoni Ribas, Ph.D., member of its Science Advisory Board, on his selection as President-Elect for The American Association for Cancer Research (AACR).  Dr. Ribas officially became President-Elect on April 1st at the 2019 AACR Annual Meeting in Atlanta and will assume the presidency at next year’s AACR Annual Meeting in San Diego. Elected by the members of the AACR, he joins five new Board members to serve on the AACR Board of Directors for the 2019–2022 term.

An expert in tumor immunology, specifically malignant melanoma, Dr. Ribas has been on ImaginAb’s Science Advisory Board since May 2018. His pioneering research has had an enormous impact on the discovery and development of new and effective treatments for malignant melanoma.

Dr Ribas is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), Director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA, and Chair of the Melanoma Committee at SWOG.

“We congratulate Toni on his new position as President-Elect of AACR,” said Ian Wilson, CEO of ImaginAb. “An extremely prestigious role, it reflects not only Toni’s immense knowledge and expertise in the field of immuno-oncology, but also his invaluable role as a mentor for oncologists and cancer researchers.  We continue to benefit hugely from the wealth of experience he brings to ImaginAb.”

“It is a great honor to be elected by my peers as the President-Elect of AACR, “said Dr. Ribas. “In this time of remarkable and rapid advancement in our understanding of cancer, we have made great strides at improving treatments, but it is not enough. I believe AACR has to continue to advocate for public policy and funding to support cancer research and the development of new treatments, which is the best investment we can make in our futures. I look forward to working with researchers, clinicians, policymakers, patient advocates, caregivers and patients to pursue the common goal of defeating cancer.”

ImaginAb’s other Science Advisory Board members include; James P. Allison, Ph.D.; Jeffrey L. Evelhoch, Ph.D., Ramy Ibrahim, M.D., David Mankoff, M.D., Ph.D., Padmanee Sharma, M.D., Ph.D., and Daniel D. Von Hoff, M.D., F.A.C.P.

For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.

Inquiries:

ImaginAb

Ian Wilson

Email: info@imaginab.com

Phone: +1 310 645 1211

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur

Email: imaginab@optimumcomms.com

Phone: +44 20 3950 9144

About ImaginAb

ImaginAb Inc. is an immuno-oncology imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also developing a pipeline for other targets in oncology. ImaginAb’s products have the potential to improve patient care and lower healthcare costs.

For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.

About Dr. Antoni Ribas, M.D., Ph.D.

Dr. Ribas is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), Director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA, and Chair of the Melanoma Committee at SWOG. Dr. Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene-engineered T cells, PD-1 blockade and BRAF targeted therapies. His National Cancer Institute (NCI), State of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options, studies mechanism of action of treatments in patients and the molecular mechanisms of therapy resistance. Dr. Ribas is an elected member of the American Society of Clinical Investigation (ASCI), has a Doctor Honoris Causa from the University of Buenos Aires, the recipient of the 2014 AACR Richard and Hinda Rosenthal Award, the 2018 AACR-CRI Lloyd J. Old Award in Cancer Immunology and an NCI Outstanding Investigator Award.

Dr. Ribas received his doctorate from the Autonomous University of Barcelona, Spain, and his medical degree from the University of Barcelona. After serving as an intern and resident at the University Hospital Vall d’Hebron in Barcelona, he moved to UCLA, joining the faculty in 2001.

About the American Association for Cancer Research

The AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers and increase public understanding of cancer. www.aacr.org